Full data from OST-HER2 Phase 2b osteosarcoma trial, including synthetic control arm data being developed at the request of FDA to support a Breakthrough Therapy Designation request, to be ...

A few months later, in May 2023, she was undergoing another routine scan when her doctors found another tumour in her arm – a reoccurrence of osteosarcoma. “I just burst into tears and I ...

OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a strong immune response against cancer cells expressing HER2.

An event in this case is defined as the recurrence of metastatic osteosarcoma ... 21 centres between the ages of 12 to 39 into a single arm. All were dosed 16 times, once every three weeks ...